iOS app Android app

Biologics

Once Again, Inaction at the FDA, Now With a New Class of Drugs, Hurts Consumers

Paul Alexander | Posted 07.10.2014 | Politics
Paul Alexander

Recently, Phil DeLuca, a retired Long Island Railroad worker, was profiled on a national news television program. Suffering from a potentially fatal red blood cell deficiency, he receives a weekly shot of Procrit. Simple enough, but that shot costs a staggering $1,500, of which his co-pay is $196.

The HIV Pandemic: Turning the Global Tide

Gary Puckrein | Posted 10.07.2012 | Black Voices
Gary Puckrein

Thirty years in, the U.S., indeed the planet, is making great strides in HIV and AIDS research. Dr. Fauci's vision of an AIDS-free generation will only be realized with innovative biologic and biosimilar medicines that are effective in and accessible by all affected populations.

Zach Carter

Obama's Global Health Policy Undercuts Reform At Home

HuffingtonPost.com | Zach Carter | Posted 07.10.2012 | Politics

WASHINGTON -- A few hours after the Supreme Court upheld his signature health care legislation last week, President Barack Obama approached a White Ho...

Approved Pathway for Biosimilars Must Be Patient-Focused

Eva M. Clayton | Posted 08.25.2012 | Healthy Living
Eva M. Clayton

The U.S. pharmaceutical industry has worked hard to become an international leader in the production of biotech drugs. But as the nation introduces these medicines, we need to ensure that safety protocols are in place -- so that every patient has the opportunity to get healthy.

Drug Shortages and You: Who's At Risk, What's the Fix?

John Horton | Posted 05.09.2012 | Politics
John Horton

Drug shortages are a complex problem with multiple causes, not least of all manufacturing issues that can affect the safety of injectable medicines like biologics.

Medical Innovation and Shortening the Long Goodbye

John Horton | Posted 02.20.2012 | Healthy Living
John Horton

Today, too many families face President Reagan's "long goodbye" -- and too many Alzheimers' victims know, even as the disease begins to rob them of their memories, of the pain their families will face.

Patient Safety Paramount for Cutting Edge Medicines

Gary Puckrein | Posted 02.05.2012 | Black Voices
Gary Puckrein

It is crucial that the health care communities in both the public and private sector transform their data collection and testing approaches to account for the overall changing face of the American population.

Data Exclusivity: Getting the Balance Right

John Horton | Posted 07.19.2011 | Politics
John Horton

What's the right length for data exclusivity? The current law says innovator drug makers have twelve years; in the European Union, it's ten; and the 2012 budget proposes seven. Who's right?

Let's Not Return to the Days of Health Insurance Abuse

Sen. Sherrod Brown | Posted 05.25.2011 | Politics
Sen. Sherrod Brown

In America, a family should never be forced into bankruptcy because a child gets sick. In America, an Ohio family shouldn't be denied coverage if it r...

Biologic Drugs May Be Cheaper, But Are They Safe?

John Horton | Posted 05.25.2011 | Home
John Horton

Biologics are an exciting new world of medicine. But the EMA's new guidelines should put patient safety first by requiring biosimilars to be held to the same safety and standards as the original drug.

Are Unsafes Drugs An 'Acceptable Risk?' FDA Should Say 'No!'

John Horton | Posted 05.25.2011 | Home
John Horton

As a matter of common sense, the FDA's process for biosimilars shouldn't sacrifice patient safety.

Anna Eshoo's PhRMA Boondoggle: The Devil Is In Her Details

Jane Hamsher | Posted 05.25.2011 | Politics
Jane Hamsher

Thank you, Rep. Eshoo, for your commitment to having a bill that does not allow for "evergreening." Now the question becomes -- how are we going to get one?

Biologics: The Case for 13 or More Years of Data Exclusivity

Pat Choate | Posted 05.25.2011 | Technology
Pat Choate

The United States will only realize this potential and remain the global leader in medical innovation if we maintain a strong environment for investment in the newest wave - biopharmaceuticals, also known as biologics.

Protecting Pharmaceutical Profits: The Cost Is Human Lives

Jane Hamsher | Posted 05.25.2011 | Politics
Jane Hamsher

The public option has received the lion's share of attention in the health care debate, but there's an equally important issue relating to generic drugs that could mean lifesaving drugs remain too expensive for all but the wealthy.

Before We Pass Health Insurance Reform, We Must Do More to Limit Big Pharma's Monopoly on Biologics

Marcy Winograd | Posted 05.25.2011 | Politics
Marcy Winograd

In Congress, I will work to support affordable prices on biologics, so that victims of cancer, HIV, diabetes, Parkinsons, rheumatoid arthritis, and multiple sclerosis can afford the medicine they need to stay alive.

The Fight For Biogenerics

Hilary Kramer | Posted 05.25.2011 | Politics
Hilary Kramer

You know a health care bill isn't right for the American people when it carves out a legal monopoly for Big Pharma and Botox. Our Congressional leaders should be capable of more.

A Little-Discussed Issue That Puts "Care" Back in Health Care Reform

Kate Kelly | Posted 05.25.2011 | Politics
Kate Kelly

Legislation concerning the changes for the drug approval process on a special type of medicine (biologic medicines) could provide huge savings -- a major need with health care reform.

House Health Care Bill: A Death Sentence For My Fellow Breast Cancer Survivors

Jane Hamsher | Posted 05.25.2011 | Politics
Jane Hamsher

Pelosi made a choice about the lifesaving biologic drugs I took when I was in chemotherapy that will cost many fellow breast cancer survivors everything they own, and quite possibly their lives.

Why We Can't Forget about HIV/AIDS in Health-Care Reform

David Mixner | Posted 11.17.2011 | Healthy Living
David Mixner

For nearly three decades, too many people have died and millions more are living with HIV/AIDS' painful realities. Stated simply, it is far from over.